Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00168714 · ClinicalTrials.gov registry record
Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)
A clinical trial, sponsored by Biogen.
- Completed
- Registry status
- 329
- Enrollment target
NCT00168714 is a clinical trial that has completed, run by Biogen. The registered enrollment target is 329 participants.
The verdict
NCT00168714 has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- 329 participants
- Enrollment target
Study Summary
The primary objectives of the study were to prospectively record and analyze birth defects and spontaneous fetal losses in women with multiple sclerosis (MS) exposed to Avonex within approximately 1 week of conception or during the first trimester of pregnancy, where the outcome of the pregnancy was unknown prospectively and to prospectively record and analyze pregnancy outcomes in an exploratory fashion of women with MS who stopped therapy, but who may have been exposed to Avonex with approximately 1 week of conception or during the first trimester of pregnancy.
Interventions
- DRUG BG9418 (interferon beta-1a)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 329 participants |
| Start Date | 2004-02 |
| Est. Completion | 2011-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00168714
The ClinicalTrials.gov registry entry for NCT00168714 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 329 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BG9418 (interferon beta-1a) is the first listed.
NCT00168714 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00168714 about?
NCT00168714 is a clinical study titled "Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)". The primary objectives of the study were to prospectively record and analyze birth defects and spontaneous fetal losses in women with multiple sclerosis (MS) exposed to Avonex within approximately 1 week of conception or during the first trimester of pregnancy, where the outcome of the pregnancy was...
What is the current status of trial NCT00168714?
This trial is currently completed. The enrollment target is 329 participants. The study started on 2004-02. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00168714?
The interventions under investigation include: BG9418 (interferon beta-1a) (DRUG).
Who is sponsoring clinical trial NCT00168714?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.